Accelrys, Inc.’s Discovery Studio life sciences modeling and simulation software predicts protein-protein aggregation.
GE Healthcare plans to dedicate $1 billion over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities.
Prolor Biotech, Inc. reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.
Daiichi Sankyo Co., Ltd. and AstraZeneca KK announced the launch of Nexium Capsule (esomeprazole magnesium) 10mg and Nexium Capsule 20mg in Japan following the NHI (National Health Insurance) drug price listing received on September 12, 2011.
Lonza’s 4D-Nucleofector Y unit enables adherent nucleofection of neural cells grown in 24-well tissue culture plates. For transfection, disposable conductive polymer 24-well dipping electrode arrays are inserted into the culture plate.
SeraCare Life Sciences’ Cryo-T8 Human CD8+ T-cells and Cryo-B Human CD19+ B-cells include a range of donor demographics and related HLA information
Scientists at Johns Hopkins University School of Medicine have replaced the DNA in the arm of a yeast chromosome with computer-designed, synthetically produced DNA that is structurally distinct from its original DNA to produce a healthy yeast cell.
An Oak Ridge National Laboratory invention able to predict three-dimensional structures of protein could impact drug discovery and human health.
Researchers have developed a mouse genetic blueprint that may explain human genetics. Led by researchers at the Wellcome Trust Sanger Institute and the University of Oxford, the international team decoded and compared the genome sequence of 17 mouse strains.
Agilent Technologies Inc. and the Agilent Technologies Foundation announced that professor Gerhard Wagner, Harvard Medical School, has received an Agilent Thought Leader Award in support of his work using high-magnetic-field nuclear magnetic resonance (NMR) spectroscopy to analyze large proteins.
NanoBio Corporation announced a licensing agreement with the National Institutes of Health in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.
Nanobiotix announced that its lead compound NBTXR3 received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.
MorphoSys AG announced that Bayer HealthCare Pharmaceuticals initiated a Phase 1 clinical trial with the HuCAL-derived antibody-drug conjugate, BAY 94-9343, in the therapeutic area of oncology.
Avila Therapeutics Inc. completed 28 days of dosing of the first cohort of patients in its Phase 1b clinical trial of AVL-292 and is advancing to the second dose cohort in this trial.
Nearly 60% of all protocols used in clinical trials for new drugs are amended during the trial.